Skip to main content
Clinical Trials/NCT04818918
NCT04818918
Recruiting
Not Applicable

Study of the Relationship Between Coronary Flow and Myocardial Viability: the Single-centre, Observational, Prospective FloVITA Study

Centre Hospitalier Universitaire de Besancon1 site in 1 country45 target enrollmentMay 19, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
Centre Hospitalier Universitaire de Besancon
Enrollment
45
Locations
1
Primary Endpoint
Coronary flow (mL/min) in the LAD
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Evaluation of fractional flow reserve (FFR) is a key method for assessing ischemia with a view to guiding revascularization strategy following acute coronary syndrome. A stenosis that appears to be severe by angiography may cause limited ischemia (with an FFR value >0.80) due to the incapacity of the necrotic zone to achieve physiological hyperemia, i.e. maximal coronary flow. Recently, it has been demonstrated that absolute coronary flow, and micro- and macrovascular resistance, as measured by a thermodilution technique, using the Rayflow microcatheter (Hexacath) are strongly associated with myocardial mass. In extensive necrosis, there is a loss of myocardial mass, and these tools could be of potential interest in measuring myocardial viability, which reflects the extent of remaining viable myocardial mass.

Therefore, this study aims to investigate the relationship between both absolute coronary flow and microvascular resistance, and myocardial viability assessed by MRI.

In a prospective, single-centre, interventional study, we will compare absolute coronary flow and microvascular resistance in the left anterior descending artery, in patients with and without a history of ST segment elevation MI.

Registry
clinicaltrials.gov
Start Date
May 19, 2021
End Date
August 20, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria for the STEMI group:
  • ST segment elevation MI ≥7 days treated by angioplasty of the left anterior descending (LAD) artery
  • Scheduled to undergo angiography for fractional flow reserve (FFR) assessment of a lesion other than the infarct-related artery.
  • Inclusion criteria for the control group:
  • patients undergoing non-urgent coronary angiography for stable angina or silent ischemia
  • with measure of the FFR on one or more vessels (intermediate lesion \<90% without proven ischemia)
  • absence of any significant lesion on the LAD (as assessed by angiography or FFR\>0.8)
  • Inclusion criteria for both groups:
  • Written informed consent
  • Affiliation to a social security regimen (or beneficiary thereof).

Exclusion Criteria

  • Target vessel (LAD) not permeable.
  • FFR \<0.8 in the LAD
  • Coronary spasm
  • Left ventricular ejection fraction \<0.50 or a history of anterior MI in patients in the control group
  • Hypertrophic cardiomyopathy
  • Severe valvular heart disease
  • History of coronary artery bypass graft
  • Patients with limited legal capacity or patients under guardianship/tutorship
  • Patients with anticipated poor compliance as assessed by the investigator
  • Patients not affiliated to any social security regime.

Outcomes

Primary Outcomes

Coronary flow (mL/min) in the LAD

Time Frame: At the end of the angiography procedure

Measurement of coronary flow in mL/min in the left anterior descending artery

Secondary Outcomes

  • Myocardial necrosis(Cardiac MRI to be performed 7 to 30 days after index angiography procedure)
  • Microvascular resistance(At the end of the angiography procedure)

Study Sites (1)

Loading locations...

Similar Trials